Luteolin offers novel therapeutic regimen in rotenone-induced Parkinson disease via modulation of TNF-α/FXMRP/serotonin/tyrosine hydroxylase signaling pathway. NJPS [Internett]. 31. desember 2025 [sitert 14. april 2026];40(2):251-62. Tilgjengelig på: https://ojshostng.com/index.php/njphysiologicalsciences/article/view/4001